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O1
Basic Fibroblast Growth Factor (bFGF) is a Critical Microenvironmental Factor in
Human Skin for the Induction of Melanoma by UVB
C Berking, R Takemoto, K Satyamoorthy and M Herlyn
Philadelphia, PA, USA.
UV light is an epidemiological risk factor for melanoma, but its speci®c contribution to melanoma
induction is not known. The critical ®rst step of melanoma development, i.e. the uncontrolled
proliferation of melanocytes, may be induced by a combination of UV damage and an imbalance of
growth factor production by cells in the immediate environment of the melanocyte. Among
several tested cutaneous growth factors (HGF, IGF-1, PDGF-A, bFGF), overexpression of bFGF
via adenoviral gene transfer in human skin xenografted to SCID mice led to the most striking
effects on the pigment cell system. Black pigmented macules developed within 3 weeks of bFGF
treatment. Immuno¯uorescence for TRP-1, HMB-45, and Ki-67 demonstrated pathological
hyperpigmentation, proliferation and hyperplasia of activated melanocytes, but no malignant
transformation. On the other hand, when bFGF was combined with UVB, pigmented lesions with
hyperplastic melanocytic cells were detected including a lesion with high-grade atypia resembling
acrolentiginous malignant melanoma in situ. Donor-matched control grafts had no melanocyte
changes. This is the ®rst observation that an imbalance of physiological growth factor production in
the skin can cause melanoma in combination with UVB. Because bFGF was found overexpressed
in the dermal ®broblasts, global gene expression analyses of bFGF-transduced ®broblasts embedded
in collagen were performed to identify candidate paracrine factors activated by bFGF. The
melanocyte mitogen endothelin-3 was upregulated suggesting that additional physiological factors
may also contribute to melanoma development.
O2
Recessive mutation in desmoplakin disrupts desmoplakin/intermediate ®lament
interactions and causes dilated cardiomyopathy, woolly hair and keratoderma.
D.P.Kelsell1, E.E.Norgett1, S.J.Hatsell1, J.E.A.Common1, J-C.Ruiz Cabezas2, H.P.Stevens1,
L.Carvajal-Huerta2, I. M. Leigh1.
1Centre for Cutaneous Research, St.Bartholomews and the Royal London School of Medicine, QMW,
London, UK; 2Junta de Bene®cencia de Guayaquil, Guayaquil-Ecuador
Desmosomes are major cell adhesion junctions, particularly prominent in the epidermis and cardiac
tissue, and are important for the rigidity and strength of the cells. The desmosome consists of
several proteins, of which desmoplakin is the most abundant. Here, we describe the ®rst recessive
human mutation, 7901delG, in the desmoplakin gene which causes a generalised striate
keratoderma particularly affecting the palmoplantar epidermis, woolly hair and a dilated left
ventricular cardiomyopathy. Many of the patients with this syndromic disorder suffer heart failure
in their teenage years, resulting in early morbidity. All tested affected members of three families
from Ecuador were homozygous for this mutation which produces a premature stop codon leading
to a truncated desmoplakin protein missing the C domain of the tail region. Histology of the skin
revealed large intercellular spaces and clustering of desmosomes at the infrequent sites of
keratinocyte adhesion. Immunohistochemisty of skin from the patients showed a perinuclear
localisation of keratin in suprabasal keratinocytes suggesting a collapsed intermediate ®lament
network.
This study demonstrates the importance of desmoplakin in the attachment of intermediate
®laments (IFs) to the desmosome.
O3
A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+
cytolytic T lymphocytes.
ES Schultz, B Schuler-Thurner, B LetheÂ, CL Cambiaso, J Van Snick, P Chaux, J Corthals,
C Heirman, K Thielemans, T Boon, P van der Bruggen.
Brussels, Belgium and Erlangen, Germany.
Antigens encoded by MAGE-A3 and recognized by T cells are interesting targets for tumor
immunotherapy because they are strictly tumor-speci®c and shared by many tumors of various
histological types. A number of MAGE-A3 antigenic peptides presented by HLA class I molecules
have been used in clinical trials and regressions of melanoma metastasis have been observed. We
report here the identi®cation of a MAGE-A3 epitope presented to CD4+ T lymphocytes by HLA-
DP4 molecules, which are expressed in approximately 72% of Caucasians. To identify this epitope,
monocyte-derived dendritic cells were loaded with a recombinant MAGE-A3 protein and used to
stimulate autologous CD4+ T cells, obtained from blood donors without cancer. We isolated a
CD4+ T cell clone that recognized peptide TQHFVQENYLEY. Interestingly, the CD4+ T cells
lysed HLA-DP4 tumor cells expressing MAGE-A3, indicating that this epitope, in contrast to
other class-II MAGE-A3 epitopes, is presented at the surface of tumor cells. Moreover, in a
vaccination trial where patients with metastatic melanoma were immunized with peptide-pulsed
dendritic cells the majority of patients developed TH1 immunity to this epitope as revealed by
ELISPOT analysis.
O4
Functional Role of the Sodium-Hydrogen Antiporter, NHE1: Studies of NHE1 Null-
Allele Mouse Epidermis.
Martin Behne, Satoru Murata, Walter M. Holleran, Peter M. Elias, Theodora M. Mauro.
Dept. of Dermatology, U.C. San Francisco & V.A. Med. Center, San Francisco, CA.
The external layers of the epidermis, the stratum corneum (SC), shows an outward-directed,
increasingly acidic pH. Neither the origin, or the function of this gradient in normal cutaneous
function and/or disease are understood. We reported previously that: 1) permeability barrier
recovery in tape-stripped hairless mouse proceeds normally at an acidic pH, but is delayed at a
neutral pH (i.e. pH 7), due to disturbed post-secretory, extracellular lipid processing (ADR,
290:215, 1998); 2) sodium-hydrogen exchanger protein (NHE1) is present in cultured human
keratinocytes (CHK) and in the outer nucleated layers of human epidermis; and 3) CHK recovery
from an acid load (i.e. H+ export) is impeded by low-dose (10-6 M) amiloride, suggesting that
NHE1 functions to regulate both intra- and extracellular pH (pHi, pHe). To determine more
precisely the role of the NHE1 antiporter in pH regulation and subsequent SC acidi®cation, we
used both pharmacologic and molecular biology approaches. First, we used the more speci®c
NHE1 inhibitor, HOE694, which blocked recovery of CHK pHi similarly to amiloride. Topical
administration of HOE694 to hairless mice skin immediately following tape-stripping also
produced a pronounced delay in permeability recovery (by transepidermal water loss), which pH
5.5 buffer reversed, but not pH 7.4.
Finally, adult NHE1 null (-/-) mice also showed a delay in barrier recovery following
tapestripping, alterations in lamellar body secretion and post-secretory processing of extracellular
lipids to mature extracellular lamellar membrane structures, and increased SC thickness.
In summary, pharmacologic inhibition of NHE1 revealed the importance of the speci®c H+/Na+
antiporter, NHE1, for pHi, and barrier recovery, while alterations of SC structure and function in
NHE1 null mice reveal its necessity for normal barrier homoeostasis.
O5
Germline and somatic CDKN2A mutations in multiple primary melanoma patients.
MC Fargnoli1, SChimenti2, HP Soyer3, LCerroni3, P Wolf3, K Peris1.
Departments of Dermatology,1University of L'Aquila, L'Aquila,Italy; 2University of Rome ``Tor Vergata'',
Rome,Italy and 3University of Graz, Graz, Austria.
Patients with multiple primary melanomas (MPM), who develop several concomitant or successive
primary melanomas, often have a family history of melanoma. In recent studies, germline
CDKN2A mutations in MPMseries have been correlated to the familial occurrence rather than to
the melanoma multiplicity itself. In contrast, the genetics of patients with MPM in the absence of a
family history of thedisease has not yet been investigated in detail. In order to clarify the presence
of genetic predisposition to the development of multiple melanomas, we analyzed the CDKN2A
gene for germline and somatic mutations in four patients with two or more primary melanomas
and no evidence of a family history of the disease. Polymerase chain reaction and direct DNA
sequencing were used to screen the CDKN2A gene for germline mutations. Loss of heterozygosity
(LOH) and microsatellite instability (MSI) studies at 9p21(D9S974, D9S126, D9S171) were
performed in tumor specimens of each MPMpatient in laser microdissected sections by
ampli®cation of (CA)n repeat units, followed by electrophoresis of the PCR product and
hybridization with 33P-end-labeled oligonucleotides. Mutational analysis of genomic DNA
showed a germline missense mutation in exon 2 (Gly101Trp) of the CDKN2A gene in one MPM
patient who had seven independent primary melanomas resected.LOH at D9S974 has been
identi®ed in 2/7 melanoma tissues of the same patient. In addition, one of the two daughters of the
proband carried theCDKN2A mutation. Finally, LOH at D9S171 was detected in 1/4 melanomas
of a MPM patient who did not show any germline CDKN2A mutation. Based on our results, the
presence of germline mutations of the CDKN2A gene in patients with MPM but no family history
is highly suggestive of a genetic predisposition to the development of multiple melanomas. In
addition, our data support the pathogenetic role of bi-allelic inactivation of the CDKN2A gene in
melanoma development.
O6
ADAMs may be involved in the physiological shedding process of human collagen XVII.
C-W Franzke, H SchaÈcke, K Tasanen*, N Koshikawa§ and L Bruckner-Tuderman.
Dept. of Dermatology, University of MuÈnster, MuÈnster, Germany; *Dept of Dermatology, University of
Oulu, Oulu, Finland § Scripps Research Institute, Dept. of Cell Biology, La Jolla, California.
Collagen XVII is a type II transmembrane protein which occurs as a full length 180 kDa protein
and as a soluble 120 kDa form. Time chase experiments revealed that the soluble ectodomain was
®rst detectable in the medium after 9 min and was stable for more than 48 hours. New antibodies
raised against recombinant fusion proteins of the NC16A domain and the last 50 amino acids of the
C-terminus of collagen XVII demonstrated that the authentic shedding product extends from the
NC16A domain to the C-terminus of the collagen XVII molecule. The shedding was stimulated
by PMA and IL-1<FIELD symbol><98 \f ''Symbol'' \s 11¹b>, stimulators of matrix
metalloproteinases and ADAMs. To characterize the proteases involved in the shedding, normal
human keratinocytes were cultured in the presence of protease inhibitors. The shedding was
completely inhibited by phenanthroline, staurosporine, MMP- and sheddase-speci®c hydro-
xamates (BB 3103, BB 3241 and TAPI), but not by the selective gelatinase inhibitor
CTTHWGFTLC and serine protease inhibitors. Further experiments revealed that recombinant
MMP-2, MMP-9 and MT1-MMP cleaved immunoprecipitated collagen XVII only to a speci®c
product of about 140 kDa, which showed positive immunoreactivity with an endodomain speci®c
antibody and that a MMP2-de®cient human gastric carcinoma with very low MT1-MMP
expression, showed normal ectodomain shedding. Taken together all these results, it could be
assumed that MMP-2, MMP-9 and MT1-MMP may not have physiological importance in
collagen XVII shedding. Since we are able to detect the expression of the disintegrin/
metalloproteases ADAM-10 and ADAM-17 (TACE) in human keratinocytes on mRNA and
protein level, it could be speculated that these proteases are involved in the collagen XVII
processing from keratinocyte surface. In addition, it could not ruled out that a multiproteinase
cascade, consisting of furin-like proteases, metalloproteinases and ADAMs/sheddases, is involved.
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O7
a-Melanocyte Stimulating Hormone (a-MSH) as a Survival Factor in Hypoxia.
D.-H. Kalden1, 2, T. Brzoska2, G.J. Burbach1, T. Scholzen2, R. Lang1, R.A. Swerlick1,
C.A. Armstrong1, T.A. Luger2, and J.C. Ansel1.
1Dept. of Dermatology, Emory Univ. School of Medicine, Atlanta, GA, USA and 2Ludwig Boltzmann
Institute for Cell- and Immunobiology of the Skin, Dept. of Dermatology, Univ. of MuÈnster, Germany.
By virtue of location and ability to synthesize various anti-in¯ammatory as well as vasoactive
mediators, the vascular endothelium plays a key role in in¯ammation and in the maintenance of
vascular homeostasis. The neuropeptide a-MSH is a potent inhibitor of in¯ammation, and
endothelial cells (EC) are known to be a target for as well as a source of a-MSH. Hypoxic stress
activates EC to release growth factors and pro-in¯ammatory mediators. However, little is known
about the characteristics of EC death in response to hypoxia.
The aim of the present study was to test the ability of aMSH to in¯uence the survival of human
dermal microvascular endothelial cells (HDMEC) under hypoxic conditions. HDMEC were
cultivated under hypoxic conditions (0.5% O2) for 24h +/- different concentrations of a-MSH
(10-8-10-12 M). Cell viability was tested using a MTT based assay and the a-MSH precursor
proopiomelanocortin (POMC) mRNA expression was determined by quantitative RT-PCR. We
observed that hypoxia signi®cantly reduces cell viability in HDMEC. Treatment with 10-8 M a-
MSH prevents hypoxia-induced cell death. The expression of HDMEC POMC mRNA is
markedly increased under hypoxic conditions. These data provide ®rst evidence that a-MSH, in
addition to its anti-in¯ammatory capacity, may serve as a survival factor during hypoxic conditions
and suggest that it could be used therapeutically in various diseases like vasculitis, chronic wound
healing and tissue ischemia.
O8
Apo2L/TRAIL-dependent Recruitment of Endogenous FADD and Caspase-8 to Death
Receptors 4 and 5.
FC Kischkel, DA Lawrence, A Chuntharapai, P Schow, KJ Kim and A Ashkenazi.
South San Francisco, USA.
Apo2L (also called TRAIL) is an apoptosis-inducing member of the tumor necrosis factor (TNF)
family. Numerous tumors (including squamous cell carcinoma) are sensitive to apoptosis-induction
by Apo2L/TRAIL, but most normal cells (including keratinocytes) are relatively insensitive. To
begin to investigate the basis for differential sensitivity to Apo2L/TRAIL we wished to determine
its apoptosis signaling mechnism. The ligand triggers apoptosis through two distinct death
receptors, DR4 and DR5. Receptor overexpression studies have yielded con¯icting results on the
involvement of certain factors in Apo2L/TRAIL function. Here we show in non-transfected cells
that Apo2L/TRAIL induces homomeric and heteromeric complexes of DR4 and DR5, and
stimulates recruitment of the adaptor molecule FADD and the protease caspase-8, as well as
caspase-8 activation. In contrast, the adaptor molecules TRADD and RIP, which bind to TNF
receptor 1, did not bind DR4 and DR5. Thus, Apo2L/TRAIL initates apoptosis through a
mechanism similar to that used by the death ligand FasL, and FADD may be a universal adaptor for
death receptors.
O9
The In¯uence of UVA and UVB on the Tyrosine Kinase Pro®le of Normal Human
Keratinocytes.
Klosner G, Varecka R*, Trautinger F.
Division of Special and Environmental Dermatology, Dept.Dermatol., Univ.Vienna; *Boehringer-Ingelheim
Austria GmbH; Vienna, Austria
Protein tyrosine kinases (PTKs) play a signi®cant role in signalling pathways that regulate cell
proliferation, differentiation, transformation and immune responses. After exposure to stress PTKs
have been described to be involved in the induction of growth arrest and apoptosis. Exposure of
human skin to UV induces major changes in the genetic program of the exposed cells leading to
immediate and long term skin changes. Although it can be assumed that UV-induced
modi®cations of signal transduction involving PTKs regulate these processes, details as to the
speci®c changes in PTK expression after UV exposure are unknown.
To investigate PTK expression in normal human keratinocytes (HNK) we employed a reversed
transcriptase-PCR approach using degenerate primers derived from the conserved catalytic domain
of PTKs. PCR products were cloned and PTKs from randomly picked colonies (up to n = 90 per
screen) were identi®ed by sequence analysis. PTK pro®les of sham-irradiated, UVA (®ltered metal
halide lamp, 60 J/cm2), and UVB (®ltered metal halide lamp, 256 mJ/cm2) treated HNK were
analyzed 7 h after exposure. Results were analyzed by 42 test for statistical signi®cance.
We identi®ed 13 PTKs including 3 receptor kinases (axl, cak, fgfr) and 10 nonreceptor kinases
(abl1/2, ick, map4k2, fyn, yes, src, cnk, ptk6, mstr1, jak). The PTK pro®le of HNK was characterized
by a predominance of abl1/2 (46% of PTKs). Differential screening revealed a further induction of
abl1/2 expression by UVA (84 %). UVB had no in¯uence on abl1/2 but predominantly induced
the expression of the receptor kinases of the axl-family. The differences reached statistical
signi®cance at p<0.0001.
These results for the ®rst time provide information on the PTK expression pro®le of HNK and its
modi®cation by UV. The observed UV effects are wavelength dependent and affect PTKs which
are involved in the regulation of gene transcription, cell death, and proliferation. We conclude that
regulation of PTK expression is part of genetic program that mediates late effects of UVA and UVB
through speci®c alterations in phosphorylation dependent signalling cascades.
O10
Loss of expression of p16INK4a and p14ARF genes via promoter hypermethylation in human
nonmelanoma skin cancers.
A Paci®co*§, A Ouhtit§, LHGoldberg§, S Bolshakov§, K Peris*, S Chimenti**,
HN Ananthaswamy§.
§Department of Immunology, The University of Texas M.D. Anderson CancerCenter, Houston, Texas,
USA; Departments of Dermatology, University ofL'Aquila*, Italy, and Rome ``Tor Vergata''**, Rome,
Italy.
The INK-ARF locus localized on human chromosome9p21 encodes two alternative reading frame
proteins (p16INK4a and p14ARF) known to function as tumor suppressors via the retinoblastoma or
p53pathway. Inactivation of p16INK4a can lead to dysregulation of these two pathways. Although
mutations inthe p53 gene are uncommon in human melanoma, loss of the tumor suppressor
activity of p16INK4a in familial and sporadic melanoma is well documented. In addition, inactivation
of p16INK4a involving mutations, deletions or promoter hypermethylation has been found in a
variety of human tumors. However, it is not clear whether genetic alterations in p16INK4a and
p14ARF play a role in the development of human nonmelanoma skin cancer (NMSC). We,
therefore, analyzed 40NMSC (21 primary squamous cell carcinomas, 17 basal cell carcinomas and 2
actinic keratoses) for mutations in p16INK4a and p14ARF genes using PCR and SSCP techniques.
Nomutations in either the p16INK4a or the p14ARF gene were found in these tumors. However,
immunohistochemical analysis revealed loss of expression of p16 and p14 proteins in 97% of
NMSC,suggesting that hypermethylation of the promoter region may be responsiblefor the
silencing of these genes. In fact, methylation-speci®c PCR experiments showed that about 45% of
tumors had hypermethylation of p16INK4a and p14ARF promoters. As expected, about 80% of
human NMSC contained UV signature mutations in the p53 gene and about 90% of the tumors
were strongly positive for p53 immunostaining. Based onthese data, we conclude that in addition
to mutations in the p53 gene, silencing of p16INK4aand p14ARF gene expression via promoter
hypermethylation plays an importantrole in the pathogenesis of human NMSC.
O11
Targeted Expression of bcl-2 to Murine Basal Keratinocytes results in Paradoxical
Retardation of Chemical- and Ultraviolet B-induced tumorigenesis.
H.Rossiter1, S.Beissert2, C.Mayer1, M.P.SchoÈn3, B.G.Wienrich3, E.Tschachler1,4 and
T.S.Kupper5.
1D.I.A.I.D., Dept. of Dermatology, Univ. of Vienna Medical School, Vienna, Austria, 2Dept. of
Dermatology, Univ. of MuÈnster, MuÈnster, Germany, 3Dept. of Dermatology, Heinrich-Heine University,
DuÈsseldorf, Germany, 4CE.R.I.E.S., Neuilly, France, 5Dept. of Dermatology, Harvard Institutes of
Medicine, Boston, U.S.A.
In normal skin, the anti-apoptotic protein bcl-2, is present at low levels only in inter-follicular
epidermis, but becomes highly expressed in several malignant and pre-malignant epidermal
keratinocyte diseases. We have used transgenic mice that over-express human keratin-14
promoter-driven bcl-2 in the basal layer of epidermis to study the effect of deregulated bcl-2
expression on the incidence of UVB or chemically-induced epidermal tumors. Short-term UVB
irradiation results in signi®cantly fewer sunburn cells in the basal layer of the K14/bcl-2 mice than
in controls, con®rming the anti-apoptotic function of the transgene. However, K14/bcl-2, as well
as K14/bcl-2xTG.AC mice, bearing an activated ras gene, were retarded (by 3 and 2 weeks
respectively) in the time taken for 50% of mice to develop DMBA/PMA induced papillomas.
Nevertheless, eventually all mice developed similar numbers of benign papillomas, and the
conversion rate to carcinomas was similar in transgenic and control mice. UVB-induced
carcinomas appeared with a latency of 23 weeks compared to 16 weeks in K14/bcl-2 mice and
controls respectively, and signi®cantly fewer transgenic mice developed carcinomas.
Immunohistochemical analyses of the UVB-induced tumors revealed no signi®cant differences
in the degree of macrophage, neutrophil or T-cell in®ltrates. We conclude that, despite its anti-
apoptotic function, bcl-2, over-expressed in basal epidermal keratinocytes, exerts a paradoxical
retardation on the development of skin tumors induced by chemical carcinogens, and particularly,
by UVB.
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